

2021 COVID-19 Researcher Survey




On January 20, NDRI sent a request to some of our contacts, and shared a link on our LinkedIn to complete a survey regarding how the current COVID-19 pandemic has impacted studies, and how NDRI could assist with ongoing research efforts.

11% of those contacted responded and we collected these results to share with our audiences, including current researchers and the NIH. This information will be vital in learning how we can best service active researchers, and recruit new researchers moving forward.




Demographics




- This survey was sent to 2,685 researchers
- The response rate of this survey was 11% (297 researchers responded!)
- Majority of our responses came from the USA (271 researchers) but responses also came from other countries as well:
 - Canada & The United Kingdom (5 researchers per country)
 - Japan (3 researchers per country)
 - China, Switzerland, & Croatia (2 researchers per country)
 - Bulgaria, Germany, Israel, Italy, South Korea, Taiwan (Republic of China), & South Africa (1 researcher per country)


What Kind of Organization Did Each Response Come From?



Question 1. Overall, the global pandemic has impacted my teams' ability to conduct research using human tissue.



Question 2.
What do you expect to be your need for human tissue in 2021?




Question 3. Are you planning on attending any scientific conferences in 2021?

- 169 researchers said “No”
- 128 researchers said “Yes”

Question 3a. List of conferences on the next slide →

Question 3b. How will you be attending the conferences?




Question 3a. List conferences here.

Abbreviation	Conferences	# of Researchers	Abbreviation	Conferences	# of Researchers
ARVO	Association for Research in Vision and Ophthalmology	12	TERMIS	Tissue Engineering and Regenerative Medicine International Society	3
ORS	Orthopaedic Research Society	8	AAIC	Alzheimer's Association International Conference	2
SfN	Society for Neuroscience	8	ASA	American Society of Anesthesiologists	2
ATS	American Thoracic Society	7	ASCB	American Society for Cell Biology	2
AACR	American Association for Cancer Research	5	ASCO	American Society of Clinical Oncology	2
AD/PD	Alzheimer's & Parkinson's Diseases	5	ASN	American Society for Neurochemistry	2
AHA	American Heart Association	5	ASRM	American Society for Reproductive Medicine	2
ASBMR	American Society for Bone and Mineral Research	5	ASV	American Society for Virology	2
GRC	Gordon Research Conference	5	AUA	American Urological Association	2
	Keystone Symposia	5	EB	Experimental Biology	2
AAI	American Association of Immunologists	4	HIRN	Human Islet Research Network	2
ACR	American College of Rheumatology	4	IEEE	Institute of Electrical and Electronics Engineers	2
AAPS	American Association of Pharmaceutical Scientists	3	ISSCR	International Society for Stem Cell Research	2
ADA	American Diabetes Association	3	NACFC	North American Cystic Fibrosis Conference	2
ASGCT	American Society of Gene & Cell Therapy	3	OARSI	Osteoarthritis Research Society International	2
CSHL	Cold Spring Harbor Laboratory	3	SITC	Society for Immunotherapy of Cancer	2
ISMRM	International Society for Magnetic Resonance in Medicine	3	SOT	Society of Toxicology Annual Meeting and ToxExpo	2
nPOD	Network for Pancreatic Organ Donors with Diabetes	3	SPIE	International Society for Optics and Photonics	2


Question 4.
Have you received additional funding for your research during the pandemic?

- 231 researchers said “No”
- 66 researchers said “Yes”


Question 4a. If yes, where did you receive funding from?



Question 4b. If yes, was this funding for your research to study COVID-19?




Question 5. Since the onset of the global pandemic, what method of communication have you primarily been using to communicate with the research community?



*The “Other” responses included In-Person, Slack, and the Internet


Question 6. How do you receive information regarding new COVID-19 regulations or research requirements?



"Other" responses included:

- Communication from Institution/Company/University
- County Bulletins
- Industry Advocacy Associations
- Institutional Biosafety Office
- Institutional Guidelines
- Internal Taskforce
- News
- Online
- Personal Communication
- Podcasts
- Trade Associations
- Zoom meetings

Question 7. Are there any significant changes to regulatory, equipment, or facility requirements at your institution due to the COVID-19 pandemic that inhibit your ability to receive human tissue?





Question 7a. If yes, please outline these requirements.


Example of Requirements

- Access Restrictions - Buildings & Labs
- Adjusted Schedules (shift work instead of regular hours)
- Biological Safety Level (BSL) Regulations (BSL-3)
- Capacity of Work Reductions
- Centralized Deliveries / Limited Loading Dock Staff
- COVID-19 (SARS-CoV-2) testing must be performed and negative for all tissue samples.
- COVID-19 Specific Safety Training & SOPs
- Employee Health Screenings (including temperature monitoring)
- Facility Updates (including ventilation system, biospecimen cabinets, etc.)
- Hiring Freeze
- Inability to go into ER or hospital to collect samples
- Inability to perform third tier human studies (no immediate patient benefit)
- Increased Safety Requirements
- Lab Shutdowns
- Limited Availability of Core Facilities
- Limited Personnel On-Site
- Non-essential personnel (researchers) encouraged to work from home
- Occupancy / Spacing Requirements
- Physical distancing, gloves, masks at all times
- Reduced patient interaction face-to-face (telemedicine)
- Segregated Clean Facilities & Full-PPE Required

Question 8. Will your institution allow you to accept tissues/organs from donors who have previously tested positive for COVID-19 and since recovered?



Question 9. The rate of COVID-19 vaccination in the US is currently unknown and it is currently unclear how this will impact organ/tissue donation moving forward. Do you believe your future ability to accept organs/tissues for research will require that the donor has received a COVID-19 vaccine?



Publications

The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection by Brandon J. Beddingfield, Naoki Iwanaga, Prem P. Chapagain, Wenshu Zheng, Chad J. Roy, Tony Y. Hu, Jay K. Kolls, Gregory J. Bix

This project focused on potentially inhibiting SARS-CoV-2 entry through an integrin based mechanism by using ATN-161 which is an integrin binding peptide. ATN-161 inhibits the interaction between SARS-CoV-2 spike protein and its host binding partners.

